Scarica l'app Stockscreener
3.40
5.56%
-0.20
Dopo l'orario di chiusura:
3.42
0.02
+0.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.60
Aprire:
$3.6
Volume 24 ore:
2.57M
Relative Volume:
3.13
Capitalizzazione di mercato:
$337.10M
Reddito:
$9.01M
Utile/perdita netta:
$-99.72M
Rapporto P/E:
-0.7492
EPS:
-4.5381
Flusso di cassa netto:
$-92.85M
1 W Prestazione:
-15.84%
1M Prestazione:
-20.00%
6M Prestazione:
-27.04%
1 anno Prestazione:
+0.29%
Intervallo 1D:
$3.31
$3.675
Intervallo di 1 settimana:
$3.19
$4.1254
Portata 52W:
$2.80
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Nome
X 4 Pharmaceuticals Inc
Settore
Industria
Telefono
857-529-8300
Indirizzo
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
3.40 | 356.93M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-09 | Iniziato | Guggenheim | Buy |
| 2025-12-05 | Ripresa | Stifel | Buy |
| 2023-12-12 | Downgrade | B. Riley Securities | Buy → Neutral |
| 2023-08-30 | Ripresa | B. Riley Securities | Buy |
| 2022-12-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-12-12 | Iniziato | Piper Sandler | Overweight |
| 2019-12-23 | Iniziato | Oppenheimer | Outperform |
| 2019-12-18 | Iniziato | ROTH Capital | Buy |
| 2019-12-09 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-12-05 | Iniziato | B. Riley FBR | Buy |
| 2019-06-07 | Iniziato | Stifel | Buy |
| 2019-06-05 | Iniziato | Cowen | Outperform |
Mostra tutto
X 4 Pharmaceuticals Inc Borsa (XFOR) Ultime notizie
X4 Pharmaceuticals at Wells Fargo conference: trial reset lifts outlook By Investing.com - Investing.com India
X4 Pharmaceuticals (NASDAQ: XFOR) Secures FDA Approval for Reduced Sample Size in 4WARD Trial, Data Expected in Early 2028 - Kalkine Media
X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference - markets.businessinsider.com
Wells Fargo’s healthcare conference will include an X4 Pharmaceuticals talk Sept. 10 - Stock Titan
X4 Pharmaceuticals Advances Mavorixafor Strategy in Chronic Neutropenia - TipRanks
X4 posts updated corporate presentation; full 4WARD enrollment expected Q4 2026, topline data H1 2028 - TradingView
X4 Pharmaceuticals (XFOR) outlines path to possible 2029 FDA approval - Stock Titan
X4 Pharmaceuticals: FDA OKs Reduced Sample Size for 4WARD Phase 3, Enrollment to Finish by Year-End 2026 - TradingView
FDA backs smaller late-stage test of X4 (NASDAQ: XFOR) neutropenia drug, with pivotal data not due until 2028 - Stock Titan
X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting - Yahoo Finance
Layoff Tracker: TScan axes 75% of workforce, prioritizes solid tumor program - BioSpace
X4 Pharmaceuticals Stock Price Forecast. Should You Buy XFOR? - StockInvest.us
ETFs Investing in X4 Pharmaceuticals, Inc. Stocks - TradingView
X4 Pharmaceuticals Inc. (XFOR) Peer Comparison – Compare with Others - Value Research
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
X4 Pharmaceuticals Inc. (XFOR) Financials – Balance Sheet, Profit & Loss, Cash Flow - valueresearchonline.com
X4 Pharmaceuticals Inc (XFOR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission - PR Newswire
Deep Track Capital, LP Boosts X4 Pharmaceuticals (XFOR) Stake by 26.84% - GuruFocus
Is OPK Worth Buying as Valuation Meets Improving Business Trends? - TradingView
X4 (XFOR) Financial Update: Profit Per Share Clears Its Benchmark in Latest Trading; Closing Reaction - vinanet.vn
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
X4 Pharmaceuticals: Making Progress, But The Market Is Ahead Of The Trial (Rating Downgrade) - Seeking Alpha
X4 (XFOR) Share-Price Review: Closes 2.09% Lower at $4.21 in the Current Update; Price-Level Context: the Near-Term Reference Band Stretches From $4.00 to $4.42 in Latest TradingChandelier Stop - vinanet.vn
Fierce Biotech Layoff Tracker 2026: Kolon cuts workforce after ph. 3 fail; Sanofi sheds 229 staffers - Fierce Biotech
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Study Explores Industry Growth Toward $2.75 Billion - openPR.com
Perceptive Advisors (XFOR) reports 8.1% beneficial stake in X4 Pharmaceuticals - Stock Titan
Supernus Pharmaceuticals (SUPN) CMO Rubin exercises PSUs and withholds shares for tax - Stock Titan
Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk? - TradingView
4 Best Pharmaceutical Stocks for 2026 and How to Invest - The Motley Fool
Deep Track Capital (XFOR) discloses 8.33% X4 Pharmaceuticals stake with capped warrants - Stock Titan
X4 Pharmaceuticals President John Volpone Sells 24,576 Shares to Settle Tax on RSU Award - Kalkine Media
John Volpone Sells 24,576 Shares of X4 Pharmaceuticals (NASDAQ:XFOR) Stock - MarketBeat
X4 Pharmaceuticals (NASDAQ:XFOR) Chairman Sells $210,615.84 in Stock - MarketBeat
X4 Pharma chairman Craig R. sells $210,829 in shares - Investing.com
X4 Pharma chairman Craig R. sells $210,829 in shares By Investing.com - Investing.com India
X4 Pharmaceuticals Executive Chairman Adam R. Craig Sells 47,436 Shares to Cover RSU Tax Liability - Kalkine Media
X4 Pharmaceuticals, Inc SEC Filing (Aug 13, 2026) - Stock Titan
Industry Analysts Just Made A Dazzling Upgrade To Their X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Revenue Forecasts - simplywall.st
Earnings Update: X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Just Reported And Analysts Are Boosting Their Estimates - webull.com
X4 Pharmaceuticals (XFOR) Upgraded to Buy: Here's Why - Yahoo Finance
XFOR Q3 EPS Estimate Lifted by Brookline Capital Markets - marketbeat.com
Equities Analysts Issue Forecasts for XFOR FY2029 Earnings - MarketBeat
X4 Pharmaceuticals Inc (XFOR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
X4 Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
X4 Pharmaceuticals (XFOR) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
X4 Pharmaceuticals: Q2 Earnings Snapshot - Yahoo Finance
X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Yahoo Finance
X4 Pharmaceuticals (NASDAQ: XFOR) wins EU nod, posts $16.2M Q2 loss - Stock Titan
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M - BioPharma Dive
XFOR Q2'26 Earnings: EPS estimate is (0.18) USD - tradingview.com
X 4 Pharmaceuticals Inc Azioni (XFOR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):